Company news

Compugen Ltd. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Compugen's COM701 (anti-PVRIG) in Dual and Triple Combination Demonstrates Preliminary Durable Anti-Tumor Activity and Immune Activation in Patients with Platinum Resistant Ovarian Cancer

December 5, 2022

Compugen's COM701 (anti-PVRIG) in Dual and Triple Combination Demonstrates Preliminary Anti-Tumor Activity and Immune Activation in Platinum Resistant Ovarian Cancer Patients

November 30, 2022

Compugen to Participate in the JMP Securities Hematology and Oncology Summit

November 28, 2022

Compugen to Receive Milestone Payment Triggered by AstraZeneca's Phase 2 Initiation of PD-1/TIGIT Bispecific

November 15, 2022

Compugen Reports Third Quarter 2022 Results

November 13, 2022

Compugen to Participate in the Stifel Healthcare Conference

November 7, 2022

Compugen's COM701 (anti-PVRIG) Induces Potent Immune Activation in MSS-CRC Patients

November 6, 2022

Compugen's COM701 (anti-PVRIG) in Combination with Nivolumab Demonstrates Preliminary Anti-Tumor Activity and Potent Immune Activation in Metastatic MSS-CRC Patients

November 6, 2022

Compugen Announces Receipt of Nasdaq Delisting Notice

November 1, 2022

Compugen to Release Third Quarter 2022 Results on Monday, November 14, 2022

October 30, 2022

Compugen to Present New Clinical Data at ESMO-IO

October 25, 2022

Compugen to Present New Clinical and Research Data in Two Oral Presentations at SITC 2022

October 5, 2022

Compugen Letter to Shareholders

September 21, 2022

Compugen Announces Appointment of Alberto Sessa as Chief Financial Officer

September 11, 2022

Compugen to Participate in Upcoming Fierce Biotech Summit

September 6, 2022

Compugen Expands anti-PVRIG COM701 Patent Portfolio with New Composition of Matter and Use Patent in Japan

August 23, 2022

Compugen Expands anti-PVRIG COM701 Intellectual Property Portfolio

August 7, 2022

Compugen Reports Second Quarter 2022 Results

August 3, 2022

Compugen to Release Second Quarter Results on Thursday, August 4, 2022

July 20, 2022

Compugen to Present at Upcoming Industry Conferences

June 26, 2022

Compugen to Present at Upcoming Investor Conferences

May 31, 2022

Compugen Reports First Quarter 2022 Results

May 15, 2022

Compugen Announces CFO Departure

May 9, 2022

Compugen to Release First Quarter 2022 on Monday, May 16, 2022

May 1, 2022

Compugen's Computational Discovery Leverages Single Cell Spatial Transcriptomics to Gain In-Depth Understanding of the Tumor Microenvironment

March 20, 2022

Compugen To Present New Insights into the Tumor Microenvironment Using Single Cell Spatial Transcriptomics at Keystone Symposium

March 13, 2022

Compugen to Present at the Oppenheimer 32nd Annual Global Healthcare Conference

March 8, 2022

Compugen Presents New Research Suggesting Targeting DNAM-1 Axis Holds Promise for Treatment of Multiple Myeloma

March 8, 2022

Compugen Reports Fourth Quarter and Full Year 2021 Results

February 23, 2022

Compugen Announces Appointment of Dr. Mathias Hukkelhoven to its Board of Directors

February 23, 2022

Compugen to Release Fourth Quarter and Full Year 2021 Results on Thursday, February 24, 2022

February 9, 2022

Compugen to Present at the 11th Annual SVB Leerink Global Healthcare Conference

February 8, 2022

Compugen Expands COM701 Intellectual Property Portfolio with New U.S. Patent Covering Triple Combination Use with anti-PD-1 and anti-TIGIT Antibodies

January 17, 2022

Compugen Presents Preliminary Translational Data Demonstrating Immune Activation in the Tumor Microenvironment by COM701 at the TIGIT Therapies Digital Summit

December 8, 2021

Compugen Reports Third Quarter 2021 Results

November 11, 2021

Compugen Presents Preliminary Results from Phase 1 Dose Escalation Monotherapy Study of COM902 a High Affinity Anti-TIGIT Antibody at SITC 2021

November 11, 2021

Compugen Presents Preliminary Results from Phase 1/2 Dose Escalation Study of COM701 with Opdivo® and BMS-986207 (Anti-TIGIT Antibody) at SITC 2021

November 11, 2021

Compugen Presents Initial Translational Data Supporting the Differentiation of PVRIG Compared to TIGIT and PD-1 as a Novel Checkpoint on the DNAM Axis at SITC 2021

November 11, 2021

Compugen Announces Collaboration Expansion with Bristol Myers Squibb alongside $20 Million Equity Investment

November 10, 2021

Compugen to Release Third Quarter 2021 Results on Friday, November 12, 2021

October 25, 2021

Compugen Announces Milestone Payment from AstraZeneca Triggered by First Patient Dosed with TIGIT Bispecific Derived from COM902

October 3, 2021

Compugen To Present Clinical Data from anti-TIGIT COM902 Monotherapy and Triple Combination Dose Escalation Studies at SITC 2021

September 30, 2021

Compugen to Present at the Cantor Global Healthcare Conference

September 13, 2021

Compugen to Present at the Morgan Stanley 19th Annual Global Healthcare Conference

August 25, 2021

Compugen Announces Bispecific Antibody Derived from COM902 to Enter Clinical Development

August 18, 2021

Compugen Reports Second Quarter 2021 Results

July 27, 2021

Compugen Doses First Patient in Phase 1/2 Triple Combination Cohort Expansion of COM701 with Opdivo® and Bristol Myers Squibb's Anti-TIGIT Antibody, BMS-986207

July 18, 2021

Compugen Doses First Patient in Phase 1 Combination Study of COM902 and COM701 in Patients with Advanced Malignancies

July 14, 2021

Compugen to Release Second Quarter 2021 Results on Wednesday, July 28, 2021

July 13, 2021

Compugen Doses First Patient in COM701/Opdivo® (nivolumab) Phase 1b Cohort Expansion Study

June 29, 2021

← Newer news releases · Older news releases →

Calls

The 5 newest of 19 calls. Every call is listed under its year.

Decks

The 5 newest of 8 decks. Every deck is listed under its year.